Recent Public Offering by Cidara Therapeutics
Cidara Therapeutics, Inc. (“Cidara”) (NASDAQ: CDTX), an innovative biotechnology company focused on developing its proprietary Cloudbreak platform for therapeutic applications, has recently announced the pricing details of a substantial public offering. This offering includes 7,954,546 shares of common stock, each priced at $44.00 per share, all to be sold by Cidara itself.
Financial Implications of the Offering
The expected gross proceeds from this public offering stand at approximately $350 million, which is before accounting for any deductions related to underwriting discounts or expenses associated with the offering. In an interesting twist, Cidara has also granted underwriters a 30-day option to purchase an additional 1,193,181 shares at the same offering price, ensuring there's room for fluctuation based on demand.
Underwriters Involved in the Offering
A host of reputable financial institutions, including J.P. Morgan, Morgan Stanley, Guggenheim Securities, and Cantor Fitzgerald, are facilitating this offering as joint book-running managers. Their involvement highlights the significance of this offering in the capital markets.
Utilization of Offered Shares
The primary purpose of this offering is to boost the funding necessary for Cidara's innovative research and development programs, especially in advancing its drug-Fc conjugate (DFC) therapeutics. Such funding is vital for expanding their product pipeline, which shows great promise in the fields of oncology and infectious diseases.
Prospective Offerings and Market Availability
This offering is structured under a shelf registration statement that has already received approval from the U.S. Securities and Exchange Commission (SEC). A preliminary prospectus supplement detailing the offering is available through the SEC’s platform, and once finalized, investors will also be able to access the final prospectus.
About Cidara Therapeutics
Cidara Therapeutics stands at the forefront of medical innovation with its Cloudbreak platform. This technology enables the creation of novel DFCs, which are designed to target specific ailments such as seasonal and pandemic influenza with a long-acting antiviral candidate named CD388. This candidate recently received Fast Track Designation from the FDA.
Pipeline and Future Developments
Currently, Cidara is navigating the complexities of clinical trials effectively. Their Phase 2b NAVIGATE trial reached an enrollment milestone, enhancing their capability to evaluate CD388's efficacy. Additionally, their focus has expanded into oncology with the development of CBO421, targeting CD73 in solid tumors, for which investigational new drug application clearance was achieved.
Contact Information
For further inquiries, investors can connect with Brian Ritchie at LifeSci Advisors via telephone or email to discuss the offerings or gather more insights into Cidara’s transformative projects.
Frequently Asked Questions
What is the purpose of Cidara's recent public offering?
The public offering aims to raise funds to further support Cidara's research and development activities, particularly in enhancing its drug candidates.
What is the significance of the price set for the shares?
The share price of $44 reflects the market's valuation of Cidara's current pipeline and future potential, ensuring adequate funds for their ongoing projects.
Who are the joint book-running managers for this offering?
J.P. Morgan, Morgan Stanley, Guggenheim Securities, and Cantor Fitzgerald are handling the financial management of this offering.
What recent designation did Cidara receive from the FDA?
Cidara’s leading antiviral candidate CD388 was granted Fast Track Designation by the U.S. Food and Drug Administration.
What advancements does Cidara have in its pipeline?
The company is focusing on DFCs aimed at treating influenza, alongside a candidate for targeting solid tumors, showcasing innovative approaches across therapeutic areas.
